1. Introduction {#s0005}
===============

Lynch syndrome (LS) is considered to be responsible for high risk of early onset of colorectal cancer (CRC) and enhanced risk of many extra colonic malignancies including ovarian, endometrial, urinary tract, sebaceous gland, stomach, hepatobiliary, small bowel and central nervous system cancers ([@b0010], [@b0090]). LS account for approximately 1--3% of all CRC and 2--5% of endometrial cancer cases ([@b0050]). LS is mainly caused by germline pathogenic mutations in DNA mismatch repair (MMR) genes, mostly in four of the genes, MutL Homolog 1 (MLH1) (OMIM \# [120436](120436){#ir005}), MutS Homolog 2 (MSH2) (OMIM \# [609309](609309){#ir010}), MutS Homolog 6 (MSH6) (OMIM \# [600678](600678){#ir015}) and PMS1 Homolog 2 (PMS2) (OMIM \# [600259](600259){#ir020}) ([@b0030], [@b0045]). These conditions represent characteristic features of tumors such as microsatellite instability (MSI) and expression loss of MMR proteins (one or more) in immunohistochemistry ([@b0095]). MLH1 and MSH2 accounts for majority of the pathogenic mutations (90%), while MSH6 and PMS2 accounts for less than 10% accumulative mutations underlying LS ([@b0130]). Furthermore, recent studies have included EPCAM gene (OMIM: [185535](185535){#ir025}) as also main cause of LS and accounts for 1--3% of all LS patients ([@b0070], [@b0015]).

The UK National Institute for health and care excellence (NICE) in their strategy has emphasized to screen routinely all of the patients with newly diagnosed CRC, irrespective of age for these four MMR genes (([@b0005]). Early screening of MMR gene mutations in the relatives of the patients helps in reducing morbidity and mortality ([@b0020]). Therefore, it is necessity for health care providers to identify the LS families, screen and recommend preventive measure to decrease the cancer risk as well as the financial burden for lifelong testing and treatments ([@b0140]).

In general, germ line mutational analysis of MMR genes is done to identify LS patients, however, we attempted going to the next level for identification of copy number variants that likely change the function of the encoded MMR proteins and pathways ([@b0155]). In the present research, we have performed genome-wide high density array CGH analysis in the LS patients to characterize genomic alterations accountable for these disorders. Our current study shall pave the way further for the accumulation of LS prevalence in Saudi Arabia and its underlying genotypic rearrangements. Once the full mutational spectrum is known, then it will be easy to establish a rapid genetic testing platform and screen the patients and carriers with this syndrome.

2. Materials and methods {#s0010}
========================

2.1. Sample collection and DNA extraction {#s0015}
-----------------------------------------

We ascertained 12 samples of LS ([Table 1](#t0005){ref-type="table"}). Clinical investigation was obtained from patients and clinicians and confirmed the LS as per revised guidelines of Bethesda and Amsterdam criteria ([@b0135]). Authorization to conduct study was taken from all patients prior to the start of study according to the Helsinki\'s declaration. The study was approved from local ethical committee of Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia and conducted here during the period of December 2017 to March 2019. The DNA was extracted from tumor tissue of the samples according to the standard procedure (Qiagen, USA) and quantified (ND-1000).Table 1Clinicopathological characteristics including age, gender, tumor location, size, stage and lymph nodes status of twelve Lynch Syndrome patients.Sample No.AgeGenderGrade[\*](#tblfn1){ref-type="table-fn"}Tumor location[\#](#tblfn2){ref-type="table-fn"}Tumor size (cm)Tumor stageLN status[\$](#tblfn3){ref-type="table-fn"}**P1**34M217.031**P2**47F328.031**P3**32F327.542**P4**39M328.031**P5**31F222.031**P6**44F222.021**P7**43M219.032**P8**36M223.032**P9**35M223.531**P10**43F2112.031**P11**49M327.532**P12**38M111.531[^1][^2][^3]

2.2. Array comparative genomic hybridization profiling {#s0020}
------------------------------------------------------

Array CGH was performed on the DNA samples from colorectal tumor tissue of the patients and keeping healthy adjacent tissue as control (sureprint G3 Human CGH 2x400 K arrays kit, Agilent, USA).

2.3. Chip processing and bioinformatics data analysis {#s0025}
-----------------------------------------------------

Chip scanning was done on Agilent scanner (G2505C), image analysis and data extraction was done by Feature Extraction Software (V.1.5.1.0, Agilent). CGH array profiling was performed by Cytogenomics v2.7 software (Agilent) for visualization, detection and analyzes alterations.

2.4. Quantitative PCR {#s0030}
---------------------

For the validation of copy number variations/deletions and duplications detected by cGH array experiments, we used Real-time quantitative PCR. The primers were designed for the MLH1, MSH2, MSH6, EPCAM, PMS2 and MUTYH genes and an endogenous gene Actin Beta (ACTB) was taken as an internal control.

3. Results {#s0035}
==========

3.1. Clinicopathological study {#s0040}
------------------------------

We included twelve LS patients under the age of 40 years, seven of them were males and five were females. Histopathological study of LS patients revealed around 65% cases in grade 2 (moderate grade) followed by grade 3 (poor grade) of 30%. Surprisingly, 80% tumors were located on right side of the body. Tumor size were variable ranging from 2 cm to 12 cm ([Table 1](#t0005){ref-type="table"}).

3.2. Array CGH study {#s0045}
--------------------

We identified more than hundred alterations (gain or loss) with mean log2 ratio cut off value of ±0.25. For single copy number deletion or amplification cut off mean log ratio was −1.0 and 0.58 respectively. We filtered the result to focus on genomic alterations associated with LS and identified four alterations, all were structural losses, encompassing LS genes ([Table 2](#t0010){ref-type="table"}). We detected 2p21-p16.3 (MSH2, MSH6, EPCAM) in eight ([Fig. 1](#f0005){ref-type="fig"}), 3p23-p14.2 (MLH1) in five ([Fig. 2](#f0010){ref-type="fig"}), 7p22.1 (PMS2) in two ([Fig. 3](#f0015){ref-type="fig"}), and 1p34.1-p33 (MUTYH) in one LS patients. ([Fig. 4](#f0020){ref-type="fig"}).Table 2Array CGH analysis based detection of genomic alterations of the Lynch syndrome genes *MSH2, MSH6, EPCAM, MLH1, PSM2, and MUTYH.*CytobandSize (kb)ProbesMean Log RatioCopy NoTypep-valGene Name**2p21-p16.3**828.608154−0.6081Loss1.37E-20**EPCAM**, MIR559, **MSH2**, KCNK12, HCG2040054, **MSH6**, FBXO11...**3p23-p14.2**27363.24574−0.2591Loss2.76E-216STAC, DCLK3, TRANK1, EPM2AIP1, **MLH1**, LRRFIP2, GOLGA4...**7p22.1**830.844128−0.7861Loss7.65E-14RSPH10B2, **PMS2**, AIMP2, EIF2AK1, ANKRD61, CYTH3, RAC1...**1p34.1-p33**1610.385309−0.5961Loss1.76E-13HECTD3, UROD, ZSWIM5, LINC01144, HPDL, **MUTYH**, TOE1, TESK2, CCDC163, MMACHC...[^4]Fig. 1Whole genome array CGH analysis (2x 400 K) showing structural loss in 2p21-p16.3 region, a locus for MSH2, MSH6 and EPCAM genes. Copy number variation is detected by cut off mean log~2~ ratio of ±0.25, where red and blue color indicates loss and gain respectively.Fig. 2Whole genome array-CGH analysis (2x 400 K) showing structural loss in 3p23-p14.2 region, a locus of MLH1 gene. Copy number variation is detected by cut off mean log~2~ ratio of ±0.25, where red and blue color indicates loss and gain respectively.Fig. 3Whole genome array CGH (2x 400 K) analysis showing structural loss in 7p22.1 region, a locus for PMS2 gene. Copy number variation is detected by cut off mean log~2~ ratio of ±0.25, where red and blue color indicates loss and gain respectively.Fig. 4Whole genome array CGH (2x 400 K) analysis showing structural loss in 1p34.1-p33 region, a locus for MUTYH gene. Copy number variation is detected by cut off mean log~2~ ratio of ±0.25, where red and blue color indicates loss and gain respectively.

3.3. Validation by qPCR {#s0050}
-----------------------

Genomic alterations and genes located on these regions were confirmed by real time quantitative PCR technique by calculating mean Rq values of genes; MLH1 (0.725), MSH2 (0.611), MSH6 (0.667), EPCAM (0.510), PMS2 (0.359) and MUTYH (0.593) ([Fig. 5](#f0025){ref-type="fig"}). This result confirms that genes causing LS were less expressed as detected in array CGH.Fig. 5Real time quantitative PCR analysis of MSH2, MSH6, EPCAM, MLH1 and MUTYH genes showing down expression in Lynch Syndrome. Gene expression is measured in term of mean relative quantification (Rq) values cut off ±1, where 1 is normal expression and Rq value more or less than 1 are indicator of up or down expression.

4. Discussion {#s0055}
=============

Disturbance to genomic stability or errors in DNA replication are significant threat to regular cell division process. MMR genes, proteins and pathways correct any unwanted changes and work as tumor suppressor. However, loss of function in MMR leads to sporadic cancer and germline mutation in MMR genes leads to hereditary cancer like LS ([@b0150], [@b0075], [@b0065], [@b0055], [@b0100]). MLH1 and MSH2 were identified as most mutated MMR genes associated with LS ([@b0105], [@b0080]). Several mutations identified in LS falls under missense or nonsense categories, however other pathogenic variants are small insertions/deletions or large genetic rearrangements (large deletions/insertions) ([@b0025], [@b0085]). We conducted array-CGH based study of LS to identify the chromosomal abnormalities in genome and confirm the alteration in MMR genes regions.

Array CGH analysis detected structural loss in the genomic regions of MLH1 (3p23-p14.2), MSH2, MSH6, EPCAM (2p21-p16.3), PMS2 (7p22.1) and MUTYH (1P34.1-p33) in LS patients. MLH1 (homolog to MutL gene of E. coli) is involved in DNA mismatch repair and positioned at 3p22.2. The mutations in this gene were first described by [@b0120] to cause LS ([@b0120]). MSH2 (homolog to the E. coli MutS gene) is located on chromosome 2p21-p16 and is involved in DNA mismatch repair ([@b0035]). MSH6 is located at 2p16.3 and also involved as DNA MMR gene ([@b0040]). The EPCAM gene is located on 2p21 and encodes a carcinoma-associated antigen ([@b0110]). PMS2 is positioned at 7p22.1, is also a MMR gene and showed to be in involved in hereditary colon cancer ([@b0120]). MUTYH (Homology of *E. coli* mutY) is a DNA repair gene located on chromosome 1 at position 34.1 ([@b0125]).

MLH1, MSH2, PMS1, PMS2, and MSH6 proteins interact with each other, however, defects in protein-protein interactions (PPI) have shown strong link with missense mutations in specific regions of these genes ([@b0160], [@b0115]). The loss of function of any one of MMR protein prevents proper function of mismatch repair\'s complex and these variants disrupting the crucial PPI may increase risk for tumorigenesis in LS ([@b0145], [@b0160]).

Current study is very useful in Saudi perspective as consanguineous marriages are common in the society and family is generally big. Therefore, the risks for transferring genetic alterations to the next generations in the region is higher as compared to Europe and America, where the consanguineous marriages are lower and family size is generally small. Once the mutation is established in an individual it also allows screening for the same alteration in extended family members. So, the identification of the carriers of the MMR gene mutation is very important because it will allow them to undergo early testing and routine surveillance of LS. Regular colonoscopy screening has helped to reduce the mortality rate from CRC in mutation carriers ([@b0060]).

5. Conclusion {#s0060}
=============

In the present study we did genome-wide profiling of 12 Saudi Lynch syndrome patients with healthy controls. We have reported loss of copy numbers with Lynch syndrome genes at 2p21-p16.3 (MSH2, MSH6, EPCAM), 3p23-p14.2 (MLH1), 7p22.1 (PMS2), and 1p34.1-p33 (MUTYH). We found lower expression of MLH1, MSH2, MSH6, PMS2, EPCAM and MUTYH genes that confirms the loss of copy number in affected regions. Our finding in genome-wide profiling might lead to novel therapeutical intervention in the future and reducing the health care burden in the society.
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[^1]: Grades: 1 = well, 2 = moderate, and 3 = poor.

[^2]: Tumor location: 1 = Right and 2 = Left.

[^3]: LN status: 1 = negative and 2 = positive.

[^4]: Bold is made to signify the pathological importance of key genes associated with Lynch syndrome.
